<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151412">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01985789</url>
  </required_header>
  <id_info>
    <org_study_id>PHPY2013/14</org_study_id>
    <nct_id>NCT01985789</nct_id>
  </id_info>
  <brief_title>Anti-histamines and Methacholine Challenges.</brief_title>
  <official_title>The Effect of Antihistamines on Methacholine Challenge Testing in Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Don Cockcroft</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The asthmatic airway is identified and studied using inhaled agents such as histamine and
      methacholine.  The use of antihistamines prior to the test will inhibit the test result if
      histamine is used to cause airway constriction.  If using methacholine, this may also be
      true depending on whether old (e.g. benadryl) or new (e.g. desloratadine) antihistamines are
      used.  This study will look at the effect of old and new antihistamines on inhaled
      methacholine challenge response in individuals with mild asthma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>change in methacholine pc20</measure>
    <time_frame>change from baseline (pre dose) at 2 hours (post dose)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>diphenhydramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg dose given as two 25mg capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cetirizine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg dose given as 1 10mg capsule and 1 placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>desloratadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg dose given as 1 5mg capsule and 1 placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>given as 2 placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <arm_group_label>diphenhydramine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetirizine</intervention_name>
    <arm_group_label>cetirizine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <arm_group_label>desloratadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Baseline forced expiratory volume in 1s (FEV1) of 70%  or more of predicted

          -  Methacholine provocative concentration causing a 20%  fall in FEV1 16mg/ml or less

          -  No respiratory infection or change in allergen exposure for 4 weeks prior to
             screening and throughout the study

          -  No significant medical co-morbidities

          -  allergy

        Exclusion Criteria:

          -  pregnant or breastfeeding females

          -  unable to withhold antihistamines, anticholinergics, long acting bronchodilators and
             combination therapies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald W Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan, Department of Medicine, Division of Respirology, Critical Care and Sleep Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Davis, PhD</last_name>
    <phone>306-966-8291</phone>
    <email>beth.davis@usask.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beth Davis, PhD</last_name>
      <phone>306-966-8291</phone>
      <email>beth.davis@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Beth E Davis, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 8, 2013</lastchanged_date>
  <firstreceived_date>October 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>airway hyperresponsiveness</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
